According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

The ELEVATUM study's initial data showed vision improvements in patients who were given Vabysmo every eight weeks for a year.

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

A study published in Nature Medicine suggests a new experimental drug could someday help make ... a novel synthetic protein to treat macular degeneration and other incurable eye diseases that ...

Regenxbio (RGNX) announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...